Doctors from a Distance: Covid-19 and the Future of International Telemedicine

LIVE WEBINAR QCHP ACCME
Doctors from a Distance: Covid-19 and the Future of International Telemedicine Banner

Add to Calendar Doctors from a Distance: Covid-19 and the Future of International Telemedicine 11/7/2020 3:00:00 PM 11/7/2020 6:00:00 PM Asia/Riyadh Livestream false MM/DD/YYYY

Date & Location

Saturday, November 7, 2020, 3:00 PM - 6:00 PM, Livestream, Doha, Qatar

Overview

Global responses to the Covid-19 Pandemic have included emergency measures to close wards, cancel medical appointments and important operations. However, patients must still have access to doctors and other medical professionals for other medical needs. To ensure access, greater resources have been diverted towards telehealth services. The ability of patients to meet with their doctor remotely via video conferencing is not new, but the Pandemic has resulted in much greater reliance being placed on the technology. The benefits of telehealth services in the context of the pandemic are obvious. There is no risk of Covid-19 spreading during a remote video conference. Also, with resources being limited, doctors can identify which patients must go to a hospital or clinic for tests or treatment, and which patients can stay at home. At the same time, there are significant legal issues which arise. These include safety, privacy, data security, licensing, cross border liability, negligence, informed consent and more. These issues require attention from ministries, hospitals and doctors both in Qatar and abroad. The Pandemic provides an opportunity for international collaboration regarding the development of frameworks overarching the use of telehealth services. The use of the technology has propagated at an unfathomable pace, with regulators scrambling to keep up. The regulatory response should have international parity but must also be shaped to local needs and expectations. Countries around the world, including Qatar, must identify approaches to tackle these issues. As such, there are significant matters outstanding for the development of the global telehealth infrastructure which require detailed discussions between lawyers and clinicians working in the field.

Target Audience

Specialties - Allied Health Professionals, Dentists, Educators, Nurses, Pharmacists, Physicians, Researchers, Students

Objectives

1- Identify the benefits and risks of telemedicine
2- Appraise the regulatory adjustments necessary for operating telehealth in the post-Covid-19 environment
3- Examine the legal hurdles concerning cross-border telemedicine provision
4- Outline the safety and privacy concerns for institutions participating in telemedicine
5- Examine the sustainability of telemedicine for healthcare professionals and health institutions moving forward

Registration

QAR 50 or $14

Changes or Cancellations

Name changes or substitutions are not permitted.
All cancellation and refund requests must be made in writing and submitted via email to cpd@qatar-med.cornell.edu.
For a full refund of the registration fee, the cancellation request must be received at least 7 days prior to the session. No refund will be offered for cancellation request thereafter.
We will attempt to process the refund within 30 days of receiving any cancellation request.
Weill Cornell Medicine-Qatar reserves the right to cancel the course. In the event of a cancellation, fee deposit will be returned, but we will not be responsible for any other expenses including restricted or non-refundable airfare or hotel deposits.

Accreditation

Weill Cornell Medicine-Qatar is accredited as a provider of Continuing Medical Education (CME) and Continuing Professional Development (CPD) by the Qatar Council for Healthcare Practitioners (QCHP) of the Ministry of Public Health.

This activity is an Accredited Group Learning Activity (Category 1) as defined by the Qatar Council for Healthcare Practitioners-Accreditation Department and is approved for a maximum of 2.5 hours.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Weill Cornell Medicine-Qatar and Hamad Bin Khalifa University.

Weill Cornell Medicine-Qatar is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Weill Cornell Medicine-Qatar designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Relationships/Content Validity

It is the policy of Weill Cornell Medicine-Qatar to adhere to Qatar Council for Healthcare Practitioners (QCHP) and Accreditation Council for Continuing Medical Education (ACCME) Criteria, Policies, and Standards for Commercial Support and content validation in order to ensure fair balance, independence, objectivity, and scientific rigor in all its sponsored programs. All faculty participating in sponsored programs are expected to disclose relevant financial relationships pertaining to their contribution to the activity, and any discussions of off-label or investigational uses of approved commercial products or devices, or of any products or devices not yet approved in the United States and elsewhere. WCM-Q CME/CPD activities are intended to be evidence-based and free of commercial bias.

Scientific Planning Committee: Barry Solaiman, PhD, Thurayya Arayssi, MD, Deema Al-Sheikhly, MRes, MEHP, Constantina Dalassou, DDS, Nelly Khalil, MPH, Maria Paiva, PharmD, Matthew Thomas, PT, have no relevant financial relationship to disclose and will not be discussing unlabeled/unapproved use of drugs or products.

Course Directors: Barry Solaiman, PhD, Thurayya Arayssi, MD, have no relevant financial relationship to disclose and will not be discussing unlabeled/unapproved use of drugs or products.

Course Faculty: Barry Solaiman, PhD, Thurayya Arayssi, MD, Humayun Chaudhry, DO, Sophia Jan, MD, have no relevant financial relationship to disclose and will not be discussing unlabeled/unapproved use of drugs or products.

Course Faculty: I. Glen Cohen has disclosed the following: Ethics advisory board – Illuminal; Bioethics advisor – Otsuka on their MyCite product; WILL NOT BE DISCUSSING any unlabeled/unapproved use of drugs or products.

Administrative Contact: Safia Rabia has disclosed the following: Spouse, employee – Al-Wehda Medical Group; WILL NOT BE DISCUSSING any unlabeled/unapproved use of drugs or products.

ICR: Thurayya Arayssi, MD, has no relevant financial relationship to disclose and WILL NOT BE DISCUSSING any unlabeled/unapproved use of drugs or products.